Showing 7491-7500 of 8824 results for "".
- Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study of ARQ-255https://practicaldermatology.com/news/arcutis-enrolls-first-patient-in-phase-1b-alopecia-areata-study-of-arq-255/2461458/The first subject has been enrolled in a Phase 1b study evaluating Arcutis’ ARQ-255, a topical suspension of ivarmactinib, a potent and specific janus kinase 1 (JAK1) inhibitor, for the treatment of alopecia areata. ARQ-255 has been specifically formulated with Arcutis’
- Almirall Appoints Mercedes Diz as VP, Corporate Strategyhttps://practicaldermatology.com/news/almirall-appoints-mercedes-diz-as-vp-corporate-strategy/2461449/Almirall named Mercedes Diz as its VP Corporate Strategy. Diz will also join Almirall's Management Board of Directors, effective December 1. Diz joined Almirall in 2002 and, since 2021, has held the position of Senior Director of Corporate Str
- Galderma Sponsors 21st Annual SCOPE Miami Beach 2022 Art Showhttps://practicaldermatology.com/news/galderma-sponsors-21st-annual-scope-miami-beach-2022-art-show/2461447/Galderma is the exclusive aesthetic injectables sponsor of the 21st annual SCOPE Miami Beach 2022 art show. Galderma will be highlighting its aesthetics portfolio – Restylane, Dysport (abobotulinumtoxinA) and Sculptra – and hosting a variety of
- Report: AI Skin Technology on The Risehttps://practicaldermatology.com/news/report-ai-skin-technology-on-the-rise/2461428/Perfect Corp.’s latest Global Beauty Trend Report, “The Rise of AI Skin Technology” documents the rise in consumer interest in skin car
- Beekman 1802 Gives Back: Brand Celebrates World Kindness Dayhttps://practicaldermatology.com/news/beekman-1802-gives-back-brand-celebrates-world-kindness-day/2461426/Beekman 1802 will celebrate World Kindness Day, an international holiday to promote kindness throughout the world. Root
- Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in PsA, Non-Radiographic Axial Spondyloarthritis, and AShttps://practicaldermatology.com/news/bimekizumab-demonstrated-sustained-clinical-responses-to-week-52-in-phase-3-studies-in-psa-non-radiographic-axial-spondyloarthritis-and-as/2461422/Bimekizumab demonstrated sustained clinical responses to Week 52 in Phase 3 studies in psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.. The findings were presented at the ACR Convergence 2022 in Philadelphia, November 10–14, 2022. <
- Positive Results for Dermavant's Vtama in Pediatric Maximal Usage Study in Atopic Dermatitishttps://practicaldermatology.com/news/positive-results-for-dermavants-vtama-in-pediatric-maximal-usage-study-in-atopic-dermatitis/2461418/Dermavant Sciences shared positive results from its maximal usage study of Vtama (tapinarof) cream 1% in children down to age 2 years old with extensive burden of atopic dermatitis. “We are delighted with the results from our maximal usage study of Vtama cream 1% in atopic dermati
- Cutera's AviClear Now Broadly Available to US Physicians and Practitionershttps://practicaldermatology.com/news/cuteras-aviclear-now-broadly-available-to-us-physicians-and-practitioners/2461416/Cutera, Inc.’s AviClear is now broadly available to physicians and practitioners treating patients throughout North America. AviClear is the first and only energy device to be both U.S. Food and Drug Administration cleared and Health Canada approved for
- Merz’s Xeomin Taps Teyana Taylor as Brand Partnerhttps://practicaldermatology.com/news/merzs-xeomin-taps-teyana-taylor-as-brand-partner/2461412/Teyana Taylor is the latest brand partner for Merz’z Xeomin (incobotulinumtoxinA). The U.S. partnership is a continuation of the ‘Beauty on Your Terms’ campaign for Xeomin, an FDA-approved double filtered anti-wrinkle injection to temporarily improve the appearanc
- EWG: FDA Must Ban Oxybenzone in Sunscreen Now!https://practicaldermatology.com/news/ewg-fda-must-ban-oxybenzone-in-sunscreen-now/2461405/The U.S. Food and Drug Administration (FDA) should ban oxybenzone in sunscreens, according to researchers at the Environmental Working Group (EWG). For decades, sunscreen makers have used oxybenzone in their products, despite concerns about its health harms. In 2021, the FDA t